Petros Grivas, MD, PhD; Rana R. McKay, MD; Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS discuss how to personalize treatment intensification in metastatic castration-sensitive prostate cancer by considering clinical factors like disease volume, patient fitness, genomic biomarkers, and emerging trial data to guide decisions between doublet versus triplet therapy regimens.
Tina Cascone, MD, PhD; Josh Reuss, MD; Wade Iams, MD, MSCI; Aditya Juloori, Tina Cascone, MD, PhD; Josh Reuss, MD; Wade Iams, MD, MSCI; Aditya Juloori, MD; Brendon Stiles, MD; and Mara Antonoff, MD, FACS, discuss how the evolving landscape of early-stage non–small cell lung cancer (NSCLC) treatment has been transformed by neoadjuvant and perioperative chemoimmunotherapy approaches, with recent data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from CheckMate 816 and CheckMate 77T demonstrating significant overall survival benefits while highlighting the critical importance of multidisciplinary collaboration, biomarker-guided personalization, and managing surgical attrition rates to optimize patient outcomes.
Panelists discuss the significant advancements in metastatic melanoma treatment over the past decade, including targeted therapies and immunotherapy, to help clinicians navigate the evolving therapeutic landscape and improve patient outcomes.
Sam Klempner, MD; Michael K. Gibson, MD, PhD; Kaitlyn Kelly, MD, MAS; and Nataliya Uboha, MD, PhD, discuss how the positive results from the phase 3 MATTERHORN trial, which demonstrated that adding durvalumab to perioperative FLOT chemotherapy significantly improved event-free survival in patients with resectable gastric and gastroesophageal junction cancers, establishes a new standard of care that they plan to implement in clinical practice while addressing practical considerations around patient selection, multidisciplinary coordination, and managing the toxicity profile of this combination regimen.
Panelists discuss the evolving landscape of breast cancer surveillance, focusing on circulating tumor DNA testing for molecular residual disease detection, recent clinical data supporting its use, and practical strategies for integrating this technology into posttreatment monitoring.
Panelists discussed evolving strategies in limited-stage and extensive-stage small cell lung cancer (LS-SCLC and ES-SCLC), including the integration of consolidation durvalumab in LS-SCLC, emerging first-line chemoimmunotherapy regimens in ES-SCLC, maintenance strategies such as atezolizumab plus lurbinectedin and durvalumab plus tarlatamab (DeLLphi-305), and the promising future role of novel agents like T-cell engagers, antibody-drug conjugates, and B7-H3–targeted therapies (including DeLLphi-304) in reshaping the treatment landscape.
Shreyaskumar R. Patel, MD; Priscilla Merriam, MD; Richard F. Riedel, MD; and Gina Z. D'Amato, MD, discuss how gastrointestinal stromal tumors require comprehensive mutational analysis to guide targeted kinase inhibitor therapy, emphasizing the importance of patient adherence, proactive adverse effect management, and maintaining some form of kinase inhibition even after progression to maximize disease control and quality of life.
Joshua Sabari, MD; Christine Bestvina, MD; Hatim Husain, MD; and Julia Rotow, MD, discuss how targeted therapies for KRAS G12C and ALK::ROS1 fusion-positive advanced non–small cell lung cancer are evolving from second-line treatments to promising frontline combinations with immunotherapy, emphasizing the critical importance of comprehensive biomarker testing and the management of unique toxicity profiles as these next-generation inhibitors demonstrate improved efficacy and central nervous system penetration.
Panelists discuss the latest data on first-line treatment options for EGFR-mutated NSCLC, including CNS efficacy, and explore strategies for managing adverse events and sequencing therapies to optimize long-term outcomes.
Heather McArthur, MD; Laura Huppert, MD; Ruta Rao, MD; William J. Gradishar, MD, FACP; and VK Gadi, MD, PhD, discuss how recent ASCO 2025 data from DESTINY-Breast09 and other studies are reshaping first-line treatment decisions for HER2-positive metastatic breast cancer, with experts debating optimal sequencing strategies between trastuzumab deruxtecan (T-DXd), the CLEOPATRA regimen, and CDK4/6 inhibitor combinations while considering patient-specific factors like central nervous system metastases, hormone receptor status, and quality of life preferences.
Leslie M. Randall, MD; Thomas C. Krivak, MD; Rebecca C. Arend, MD, MPH; Tara Berman, MD, MS; and Gottfried E. Konecny, MD, discuss how molecular testing and biomarker-driven treatment strategies are revolutionizing gynecologic oncology across ovarian, cervical, and endometrial cancers.
Rebecca Shatsky, MD; Rita Nanda, MD; Kelly McCann, MD, PhD; Nusayba Bagegni, MD; and Alexis LeVee, MD,discuss how recent advances in hormone receptor–positive breast cancer treatment, including oral SERDs such as elacestrant, PI3K pathway inhibitors, and antibody-drug conjugates such as T-DXd, are being integrated into clinical practice based on biomarkers such as ESR1 mutations and HER2-low expression while addressing key sequencing decisions and resistance mechanisms in the evolving therapeutic landscape.
John L. Marshall, MD; Marwan G. Fakih, MD; Arvind N. Dasari, MD, MS, MD, and Katrina S. Pedersen, MD discuss how precision medicine has transformed metastatic colorectal cancer treatment through comprehensive molecular testing, targeted therapies like BRAF/EGFR inhibition and immunotherapy combinations for MSI-high tumors, and personalized approaches to treatment sequencing and dosing modifications that balance efficacy with quality of life considerations.
Luciano Costa, MD, PhD; Jing Christine Ye, MD, MSc; Samer Al Hadidi, MD, MS; and Binod Dhakal, MD, discuss how the multiple myeloma treatment landscape has evolved with quadruplet therapies becoming standard for newly diagnosed patients regardless of transplant eligibility, CAR T and bispecific antibodies showing promise for earlier use in relapsed/refractory disease, and emerging dual-targeting therapies potentially offering cure for some patients rather than just prolonged treatment.
Daneng Li, MD; Lowell B. Anthony, MD, FACP; Christopher Lieu, MD; and Chandrikha Chandrasekharan, MBBS, discuss how the treatment landscape for neuroendocrine tumors has evolved significantly over the past few decades with the introduction of multiple therapeutic options including somatostatin analogs, targeted therapies like everolimus and sunitinib, peptide receptor radionuclide therapy (PRRT), and the recent approval of cabozantinib, which provides new sequencing opportunities and fills treatment gaps for heavily pretreated patients while emphasizing the importance of individualized patient care and shared decision-making in this complex disease.
David C. Fisher, MD; Lauren C. Pinter-Brown, MD; Barbara Pro, MD; and Sima Rozati, MD, PhD, discuss how to optimize cutaneous T-cell lymphoma treatment through multidisciplinary care; compartment-specific therapy selection; management of treatment-related complications, such as mogamulizumab-associated rash; and strategic use of combination therapies while addressing critical unmet needs including biomarker development and improved quality of life measures.
Experts discuss key indications for alloHSCT and emerging GVHD prophylaxis strategies, as well as explore a novel investigational allogeneic T-cell immunotherapy, Orca-T, and its clinical impact in the field of transplantation.
Dr Bejanyan reports consulting or advisory role for CareDx, Medexus Pharmaceuticals, Orca Biosystems, AlloVir, TScan Therapeutics, and Pfizer; and research funding from CRISPR Therapeutics. Dr Meyer reports sponsored research from Orca Biosciences, Kyverna; and a scientific adviser role and equity holder for GigaMune, Indee, TRACT, Jura Biosciences. Dr Oliai reports no relevant disclosures (investigator on the Orca T trial funded by Orca Biosciences). Dr Gandhi reports roles with OncLive, MJH Life Sciences, OrcaBio (research), CareDx (Advisory Board). Dr Salhotra reports received funding from Rigel, Bristol Myers Squibb and Orca Biosciences; and speakers bureau for Incyte and Sanofi.
Vamsidhar Velcheti, MD, MBA, FASCO, FACP, FCCP; Jessica Donington, MD, MSCR; Jaspal Singh, MD; and Joshua Sabari, MD, discuss how optimizing early-stage non–small cell lung cancer (NSCLC) management through a multidisciplinary approach enhances treatment outcomes and improves patient care.
Andre Goy, MD; Jamie Koprivnikar, MD, and Harsh Parmar, MD, discuss how recent advancements in CAR T-cell therapies, bispecific antibodies, and targeted treatments are transforming the management of hematologic malignancies, with particular focus on real-world comparative analyses of different approaches in multiple myeloma, lymphoma, and leukemia.
Experts discuss the evolving treatment landscape in advanced renal cell carcinoma (RCC), focusing on optimal treatment selection and sequencing strategies, with insights from recent clinical trial updates presented at ASCO GU 2025 and their potential impact on clinical practice.
Shubham Pant, MD, MBBS; Haley Ellis, MD; Amit Mahipal, MD; and Darshil Shah, MD, MPH, examine the evolving landscape of biliary tract cancer management, covering critical aspects from initial prognosis communication through biomarker testing strategies, first-line immunotherapy combinations, and the emergence of HER2-targeted therapies, while highlighting recent clinical trial data and ongoing challenges in optimizing patient outcomes.
Neil M. Iyengar, MD; Sara A. Hurvitz, MD, FACP; Laura Huppert, MD; Anne P. O’Dea, MD; and Melinda L. Telli, MD, discuss how recent trials, particularly DESTINY-Breast04/06, TROPiCS-02, and TROPION-Breast01, have revolutionized the HER2-low/ultralow breast cancer treatment landscape, demonstrating efficacy of novel antibody-drug conjugates such as trastuzumab deruxtecan while emphasizing the importance of careful patient selection, standardized testing, and strategic sequencing of these emerging therapies.
Cesar Rodriguez, MD; Yvonne A. Efebera, MD; Natalia Neparidze, MD; and Omar Nadeem, MD, examine how treatment approaches for transplant-ineligible/deferred newly diagnosed multiple myeloma are evolving through clinical trials like CEPHEUS, IMROZ, and BENEFIT, which demonstrate improved outcomes with anti–CD38-based quadruplet regimens while considering factors such as MRD negativity, administration methods, and patient selection criteria for optimizing therapeutic strategies.
William J. Gradishar, MD, provides insights on the evolving treatment landscape of breast cancer management, highlighting updates to NCCN guidelines, the growing role of CDK4/6 inhibitors, and anticipated research findings at ASCO 2024.
Join leading global experts as they discuss the latest research and treatment advancements in CLL from the ASH 2024 Annual Meeting. Moderated by Dr. John Seymour, this peer exchange features in-depth insights from top clinicians across Europe.
Leading experts discuss the evolving treatment landscape in diffuse large B-cell lymphoma (DLBCL), focusing on front-line therapies, second-line immunotherapies, and strategies for managing relapsed/refractory cases."
Andre Goy, MD, discusses how progress in immunotherapy and precision medicine at ASH 2024 is offering transformative insights, with JTCC highlighting the latest tumor-targeted therapies and biomarker-driven treatments that are shaping the future of personalized cancer care and improving patient outcomes.
This 12-part OncLive® Peer Exchange series, Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights, features expert-led discussions moderated by Dr. Matthew Lunning and focuses on the latest clinical data and evolving treatment strategies in relapsed/refractory follicular lymphoma. With insights from ASH 2024, including the inMIND and EPCORE NHL-2 trials, the panel explores second- and third-line therapies, bispecifics, CAR T-cell therapies, and practical guidance for optimizing patient care.
Panelists discuss how recent advances in chronic GVHD treatment, including emerging therapies like ruxolitinib, ibrutinib, and belumosudil, are reshaping management strategies by emphasizing early intervention, treatment sequencing, and the potential of combination therapies to improve patient outcomes.
Panelists discuss how recent advancements in CAR T-cell therapies, including the FDA approval of obe-cel and updates from the ZUMA-3 and FELIX trials, are reshaping the treatment landscape for relapsed/refractory ALL, with a focus on patient selection, bridging therapies, toxicity management, and health care resource utilization.
